“The solar PV business is labor intensive ... suppliers.s The platform is subscription-based and offered as a white-label solution, allowing branding and customize product pricing.

All-perovskite tandem solar cells (TSCs) are a class of solar cells comprised of two or more sub-cells that absorb light with ...

Blue Label is exploring a potential restructure of the group which may facilitate separation and potential future listing of Cell C on the Prime Segment of the Main Board of the Johannesburg Stock ...

One reason for that is that there hasn't been an easy way to label them inside cells. MIT chemists have now overcome that obstacle, demonstrating that they can label a glycan called ManLAM using ...

Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial. A phase I/II study of abemaciclib, a CDK4/6 inhibitor, in participants with ...

Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): A randomized, controlled, open label, phase II ...

Airtime Asset Transfer – Moving prepaid airtime assets from Blue Label subsidiary TPC to Cell C in exchange for new shares Debt Relief – Converting R2.1 billion of Cell C’s debt into equity ...

Circulating tumor cells (CTCs) are rare cancer cells that ... we describe detailed procedures for the production and use of a label-free spiral microfluidic device to allow size-based isolation ...

Of this, $184,002,000 (R2.9 billion) is First Priority Senior Secured Notes that Cell C issued and were publicly listed. Blue Label Telecoms, which has a 45% shareholding in Cell C, explained that ...

Blue Label Telecoms surged to its highest in almost seven years after it proposed restructuring its business to ultimately enable a listing of Cell C, South Africa’s fourth-largest wireless carrier.

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for the drug ...